“Zoetis ZTS - 15% Yearly Returns For The Next 15 Years?”Cited source: Michael Perry
AI summary · ZTS looks an interesting value investment: at a P/E of 12, high ROIC, profitable margins despite a slight revenue outlook cut, and about $2B annual cash flow against $42B market value funding buybacks/dividends. The veterinary pharma oligopoly is expected to grow 10.73%; conservative 7% growth plus buybacks/dividends gives roughly 12% total return, accepted with pharma volatility and company uncertainty on US market stabilization. Michael Perry's 15%-for-15-years view is cited, but the speaker does not adopt it, concluding ZTS is very interesting and separate from the AI bubble.
I received many questions about Zoetis, a veterinary pharmaceutical company. Of course, when there are many comments, it means that the stock is low, and this stock is significantly low.
Moreover, Michael Perry sees it as a golden investment opportunity, implying potential returns of 15% annually for the next fifteen years. This means that your investment doubles after five years, then after ten years, and then doubles again. That is equivalent to 8 times the capital.